Int J Thyroidol.  2021 Nov;14(2):170-174. 10.11106/ijt.2021.14.2.170.

Persistent Hypokalemic Paralysis in a Patient with Graves’ Disease and Gitelman Syndrome

• Jeong JW
• Yu TY

• KMID: 2522921
• DOI: http://doi.org/10.11106/ijt.2021.14.2.170

Abstract

Thyrotoxic periodic paralysis (TPP) is a potentially life-threatening condition. Graves’ disease accounts for the majority of cases of TPP. However, another diagnosis should be considered when repeated hypokalemic paralysis occurs in patients that maintain a euthyroid status. In this study, we report a case of persistent hypokalemic paralysis in a patient with Graves’ disease and Gitelman syndrome and provide a brief review of Gitelman syndrome focused on challenges with diagnosis and management when it is accompanied by TPP.

Keyword

Hypokalemic periodic paralysis; Graves; disease; Gitelman syndrome

Figure

• 

  Fig. 1 EKG with changes indicative of hypokalemia.

• 

  Fig. 2 Thyroid scan showing an enlarged thyroid gland and diffusely increased uptake of technetium-99m pertechnetate throughout both lobes (3.2% radioactive thyroid uptake).

Reference

References

1. Kung AW. 2006; Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab. 91(7):2490–5. DOI: 10.1210/jc.2006-0356. PMID: 16608889.

2. Ryu S, Yu TY, Kim HY, Cho CG. 2020; Low-dose glucocorticoid can lead to hypokalemic paralysis. Endocrine. 67(2):494–5. DOI: 10.1007/s12020-019-02133-2. PMID: 31734777.

3. Mizokami T, Hishinuma A, Kogai T, Hamada K, Maruta T, Higashi K, et al. 2016; Graves' disease and Gitelman syndrome. Clin Endocrinol (Oxf). 84(1):149–50. DOI: 10.1111/cen.12829. PMID: 26041598.

4. Oba T, Kobayashi S, Nakamura Y, Nagao M, Nozu K, Fukuda I, et al. 2019; A case of Gitelman syndrome that was difficult to distinguish from hypokalemic periodic paralysis caused by Graves' disease. J Nippon Med Sch. 86(5):301–6. DOI: 10.1272/jnms.JNMS.2019_86-505. PMID: 31105122.

5. Zha B, Zheng P, Liu J, Huang X. 2015; Coexistence of Graves' disease in a 14-year-old young girl with Gitelman syndrome. Clin Endocrinol (Oxf). 83(6):995–7. DOI: 10.1111/cen.12800. PMID: 25892104.

6. Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW, et al. 2010; Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 140(1):88–98. DOI: 10.1016/j.cell.2009.12.024. PMID: 20074522. PMCID: PMC2885139.

7. Paninka RM, Carlos-Lima E, Lindsey SC, Kunii IS, Dias-da-Silva MR, Arcisio-Miranda M. 2017; Down-regulation of Kir2.6 channel by c-termini mutation D252N and its association with the susceptibility to thyrotoxic periodic paralysis. Neuroscience. 346:197–202. DOI: 10.1016/j.neuroscience.2017.01.019. PMID: 28131627.

8. Rhee EP, Scott JA, Dighe AS. 2012; Case records of the Massachusetts General Hospital. Case 4-2012. A 37-year-old man with muscle pain, weakness, and weight loss. N Engl J Med. 366(6):553–60. DOI: 10.1056/NEJMcpc1110051. PMID: 22316449.

9. Mastroianni N, De Fusco M, Zollo M, Arrigo G, Zuffardi O, Bettinelli A, et al. 1996; Molecular cloning, expression pattern, and chromosomal localization of the human Na-Cl thiazide-sensitive cotransporter (SLC12A3). Genomics. 35(3):486–93. DOI: 10.1006/geno.1996.0388. PMID: 8812482.

10. Riveira-Munoz E, Chang Q, Bindels RJ, Devuyst O. 2007; Gitelman's syndrome: towards genotype-phenotype correlations? Pediatr Nephrol. 22(3):326–32. DOI: 10.1007/s00467-006-0321-1. PMID: 17061123.

11. Melander O, Orho-Melander M, Bengtsson K, Lindblad U, Rastam L, Groop L, et al. 2000; Genetic variants of thiazide-sensitive NaCl-cotransporter in Gitelman's syndrome and primary hypertension. Hypertension. 36(3):389–94. DOI: 10.1161/01.HYP.36.3.389. PMID: 10988270.

12. Gitelman HJ, Graham JB, Welt LG. 1966; A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians. 79:221–35. PMID: 5929460.

13. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, et al. 1996; Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 12(1):24–30. DOI: 10.1038/ng0196-24. PMID: 8528245.

14. Cruz DN, Simon DB, Nelson-Williams C, Farhi A, Finberg K, Burleson L, et al. 2001; Mutations in the Na-Cl cotransporter reduce blood pressure in humans. Hypertension. 37(6):1458–64. DOI: 10.1161/01.HYP.37.6.1458. PMID: 11408395.

15. Blanchard A, Bockenhauer D, Bolignano D, Calo LA, Cosyns E, Devuyst O, et al. 2017; Gitelman syndrome: consensus and guidance from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 91(1):24–33. DOI: 10.1016/j.kint.2016.09.046. PMID: 28003083.

16. Hsu YJ, Yang SS, Chu NF, Sytwu HK, Cheng CJ, Lin SH. 2009; Heterozygous mutations of the sodium chloride cotransporter in Chinese children: prevalence and association with blood pressure. Nephrol Dial Transplant. 24(4):1170–5. DOI: 10.1093/ndt/gfn619. PMID: 19033254.

17. Kondo A, Nagano C, Ishiko S, Omori T, Aoto Y, Rossanti R, et al. 2021; Examination of the predicted prevalence of Gitelman syndrome by ethnicity based on genome databases. Sci Rep. 11(1):16099. DOI: 10.1038/s41598-021-95521-6. PMID: 34373523. PMCID: PMC8352941.

18. Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB. Yale Gitelman's and Bartter's Syndrome Collaborative Study Group. 2001; Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int. 59(2):710–7. DOI: 10.1046/j.1523-1755.2001.059002710.x. PMID: 11168953.

19. Colussi G, Rombola G, De Ferrari ME, Macaluso M, Minetti L. 1994; Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. Am J Nephrol. 14(2):127–35. DOI: 10.1159/000168701. PMID: 8080005.

20. Ito Y, Yoshida M, Nakayama M, Tsutaya S, Ogawa K, Maeda H, et al. 2012; Eplerenone improved hypokalemia in a patient with Gitelman's syndrome. Intern Med. 51(1):83–6. DOI: 10.2169/internalmedicine.51.5723. PMID: 22214629.

21. Brambilla G, Perotti M, Perra S, Dell'Oro R, Grassi G, Pincelli AI. 2013; It is never too late for a genetic disease: a case of a 79-year-old man with persistent hypokalemia. J Nephrol. 26(3):594–8. DOI: 10.5301/jn.5000256. PMID: 23475471.

22. Larkins N, Wallis M, McGillivray B, Mammen C. 2014; A severe phenotype of Gitelman syndrome with increased prostaglandin excretion and favorable response to indomethacin. Clin Kidney J. 7(3):306–10. DOI: 10.1093/ckj/sfu029. PMID: 25852896. PMCID: PMC4377751.

23. Blanchard A, Vargas-Poussou R, Vallet M, Caumont-Prim A, Allard J, Desport E, et al. 2015; Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol. 26(2):468–75. DOI: 10.1681/ASN.2014030293. PMID: 25012174. PMCID: PMC4310664.